Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (74)

2024

  1. Correction to: Study of the intestinal microbiota composition and the effect of treatment with intensive chemotherapy in patients recovered from acute leukemia (Scientific Reports, (2024), 14, 1, (5585), 10.1038/s41598-024-56054-w)

    Scientific Reports

  2. Study of the intestinal microbiota composition and the effect of treatment with intensive chemotherapy in patients recovered from acute leukemia

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

    Haematologica, Vol. 108, Núm. 1, pp. 34-41

  2. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

  3. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  4. Evaluation of a Shotgun Metagenomics Approach for Detection of ESBL- and/or Carbapenemase-Producing Enterobacterales in Culture Negative Patients Recovered from Acute Leukemia

    Microorganisms, Vol. 11, Núm. 2

  5. FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients—efficacy and microbiologic safety

    Trials, Vol. 24, Núm. 1

  6. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

  7. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

    Cancers, Vol. 15, Núm. 2

  8. Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice

    Journal of Personalized Medicine, Vol. 13, Núm. 12

2022

  1. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

    Blood Cancer Journal, Vol. 12, Núm. 7

  2. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

    Leukemia Research, Vol. 115

  3. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

    Cancers, Vol. 14, Núm. 9

  4. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  5. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  6. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

    Leukemia, Vol. 36, Núm. 4, pp. 913-922

  7. Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD

    Therapeutic Advances in Hematology, Vol. 13

  8. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

2021

  1. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients

    Annals of Hematology, Vol. 100, Núm. 8, pp. 1995-2004

  2. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

    Leukemia, Vol. 35, Núm. 6, pp. 1571-1585